BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32696102)

  • 1. The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial.
    Cagini C; Mariniello M; Messina M; Muzi A; Balducci C; Moretti A; Levorato L; Mencacci A
    Int Ophthalmol; 2020 Dec; 40(12):3209-3215. PubMed ID: 32696102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexamethasone/Povidone Eye Drops versus Artificial Tears for Treatment of Presumed Viral Conjunctivitis: A Randomized Clinical Trial.
    Pinto RD; Lira RP; Abe RY; Zacchia RS; Felix JP; Pereira AV; Arieta CE; de Castro RS; Bonon SH
    Curr Eye Res; 2015 Sep; 40(9):870-7. PubMed ID: 25310347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis.
    Pelletier JS; Stewart K; Trattler W; Ritterband DC; Braverman S; Samson CM; Liang B; Capriotti JA
    Adv Ther; 2009 Aug; 26(8):776-83. PubMed ID: 19756415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study.
    Kovalyuk N; Kaiserman I; Mimouni M; Cohen O; Levartovsky S; Sherbany H; Mandelboim M
    Acta Ophthalmol; 2017 Dec; 95(8):e686-e692. PubMed ID: 28342227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis.
    Clement C; Capriotti JA; Kumar M; Hobden JA; Foster TP; Bhattacharjee PS; Thompson HW; Mahmud R; Liang B; Hill JM
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):339-44. PubMed ID: 20702820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
    Robert PY; Bourcier T; Meddeb-Ouertani A; Khairallah M; Zaghloul K; Amraoui A; Bhagat Y; Pop M; Cochereau I
    J Fr Ophtalmol; 2010 Apr; 33(4):241-8. PubMed ID: 20223555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops.
    Jackson WB; Low DE; Dattani D; Whitsitt PF; Leeder RG; MacDougall R
    Can J Ophthalmol; 2002 Jun; 37(4):228-37; discussion 237. PubMed ID: 12095096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of the effects of 0.1% bromfenac sodium eye drops and corticosteroids after small incision lenticule extraction].
    Jiang Y; Li Y; Jin YM; Zhang JY
    Zhonghua Yan Ke Za Zhi; 2017 Jan; 53(1):18-22. PubMed ID: 28162195
    [No Abstract]   [Full Text] [Related]  

  • 9. Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III study.
    Gallenga PE; Lobefalo L; Colangelo L; Della Loggia G; Orzalesi N; Velati P; Bujtar E; Ponte F; Damiani S; Bucci MG; Bonini S; Curatola MR; Palma LA; Bonomi L; Tomazzoli Gerosa L; Pagliarusco A; Milan E; Jauch A
    Ophthalmologica; 1999; 213(4):250-7. PubMed ID: 10420109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
    Protzko E; Bowman L; Abelson M; Shapiro A;
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of azithromycin and tobramycin eye drops on epithelial wound healing and tolerance after penetrating keratoplasty.
    Blavin J; Sauer A; Saleh M; Gaucher D; Speeg-Schatz C; Bourcier T
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):428-32. PubMed ID: 22420841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis.
    Wilkins MR; Khan S; Bunce C; Khawaja A; Siriwardena D; Larkin DF
    Br J Ophthalmol; 2011 Sep; 95(9):1299-303. PubMed ID: 21252084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis.
    Bremond-Gignac D; Nezzar H; Bianchi PE; Messaoud R; Lazreg S; Voinea L; Speeg-Schatz C; Hartani D; Kaercher T; Kocyla-Karczmarewicz B; Murta J; Delval L; Renault D; Chiambaretta F;
    Br J Ophthalmol; 2014 Jun; 98(6):739-45. PubMed ID: 24526744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children.
    Cochereau I; Meddeb-Ouertani A; Khairallah M; Amraoui A; Zaghloul K; Pop M; Delval L; Pouliquen P; Tandon R; Garg P; Goldschmidt P; Bourcier T
    Br J Ophthalmol; 2007 Apr; 91(4):465-9. PubMed ID: 17050578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis.
    Shiuey Y; Ambati BK; Adamis AP
    Ophthalmology; 2000 Aug; 107(8):1512-7. PubMed ID: 10919900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
    Pepose JS; Ahuja A; Liu W; Narvekar A; Haque R
    Am J Ophthalmol; 2018 Oct; 194():7-15. PubMed ID: 29787732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
    Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
    Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptomatic Treatment of Subepithelial Infiltrates after Viral Conjunctivitis: Loteprednol or Dexamethasone?
    Koçluk Y; Sukgen EA; Cevher S; Mat E
    Ocul Immunol Inflamm; 2017 Oct; 25(5):649-653. PubMed ID: 27015587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group.
    Hyndiuk RA; Eiferman RA; Caldwell DR; Rosenwasser GO; Santos CI; Katz HR; Badrinath SS; Reddy MK; Adenis JP; Klauss V
    Ophthalmology; 1996 Nov; 103(11):1854-62; discussion 1862-3. PubMed ID: 8942881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis.
    Rhee SS; Mah FS
    Adv Ther; 2007; 24(1):60-7. PubMed ID: 17526462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.